04.03.2024 • Sponsored • Whitepaper
How Biotechnological Advances are Transforming Monoclonal Antibody Production
This Article Collection aims to offer scientists a wealth of information on monoclonal antibody (mAb) therapy, enabling you to advance your research in this field.
What you will learn about:
- Process Analytical Technology (PAT)
- mAb purification
- Fiber-based chromatography
- High-throughput screening (HTS)
- Adaptable Drug Affinity Conjugate (ADAC) technology
© Wiley
More Information
Monoclonal antibody therapy has revolutionized treatment for diseases like cancer, offering personalized options with fewer side effects. Antibody-drug conjugates combine the precision of mAbs with chemotherapy’s toxicity, targeting specific cells effectively. Both ADCs and mAbs play crucial roles in fighting diseases, extending beyond oncology to include autoimmune diseases and infections. We hope that researchers will find this collection of articles useful in their pursuit of knowledge about the latest developments in the field of biopharmaceutical drug research and manufacturing, specifically regarding monoclonal antibodies (mAbs) and antibody-drug conjugates, as well as in precision medicine.
Articles contained in the collection:
- São Pedro, M.N. et al. (2023). Real-time detection of mAb aggregates in an integrated downstream process. Biotechnology and Bioengineering. DOI: 1002/BIT.28466.
- São Pedro, M.N. et al. (2023). Application of a fluorescent dye-based microfluidic sensor for real-time detection of mAb aggregates. Biotechnology Progress. DOI: 1002/BTPR.3355.
- Hahn, T. et al. (2023). Predictive scaling of fiber-based protein A capture chromatography using mechanistic modeling. Biotechnology and Bioengineering. DOI: 1002/BIT.28434.
- Lorek, J.K. et al. (2023). High throughput screening for rapid and reliable prediction of monovalent antibody binding behavior in flowthrough mode. Biotechnology and Bioengineering. DOI: 1002/BIT.28572.
- Eltahir, M. et al. (2022). An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies. Advanced Therapeutics. DOI: 1002/ADTP.202200008.
